CornierM.A., DabeleaD., HernandezT.L.. The metabolic syndrome.Endocr Rev2008; 29: 777–822.
2.
GrundyS.M., CleemanJ.I., DanielsS.R.. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.Circulation2005; 112: 2735–52.
3.
CurhanG.C., WillettW.C., RimmE.B., SpeizerF.E., StampferM.J.Body size and risk of kidney stones.J Am Soc Nephrol1998; 9: 1645–52.
4.
TaylorE.N., StampferM.J., CurhanG.C.Obesity, weight gain, and the risk of kidney stones.JAMA2005; 293: 455–62.
5.
TaylorE.N., StampferM.J., CurhanG.C.Diabetes mellitus and the risk of nephrolithiasis.Kidney Int2005; 68: 1230–5.
6.
CappuccioF.P., StrazzulloP., ManciniM.Kidney stones and hypertension: an independent clinical association in a population-based study.BMJ1990; 300: 1234–6.
7.
TaylorE.N., MountD.B., FormanJ.P., CurhanG.C.Association of prevalent hypertension with 24-hour urinary excretion of calcium, citrate, and other factors.Am J Kidney Dis2006; 47: 780–9.
8.
CupistiA., MeolaM., D'AlessandroC.. Insulin resistance and low urinary citrate excretion in calcium stone formers.Biomed Pharmacother2007; 61: 86–90.
9.
WestB., LukeA., Durazo-ArvizuR.A., CaoG., ShohamD., KramerH.Metabolic syndrome and self-reported history of kidney stones: the National Health and Nutrition Examination Survey (NHANES III) 1988–1994.Am J Kidney Dis2008; 51: 741–7.
10.
RendinaD., MossettiG., De FilippoG.. Association between metabolic syndrome and nephrolithiasis in an inpatient population in Southern Italy: role of gender, hypertension and obesity.Nephrol Dial Transplant2009; 24: 900–6.
11.
CarrM.C.The emergence of the metabolic syndrome with menopause.J Clin Endocrinol Metab2003; 88: 2404–11.
12.
KatoY., YamaguchiS., KakizakiH., YachikuS.Influence of estrus status on urinary chemical parameters related to urolithiasis.Urol Res2005; 33: 476–80.
13.
PriéD., RaveryV., Boccon-GibodL., FriedlanderG.Frequency of renal phosphate leak among patients with calcium nephrolithiasis.Kidney Int2001; 60: 272–6.
14.
MossettiG., RendinaD., De FilippoG., ZampaG., StrazzulloP.Phosphatonins: novel insights and clinical perspectives.G Ital Nefrol2009; 26: 171–80.
15.
PriéD., HuartV., BakouhN.. Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter.N Engl J Med2002; 347: 983–91.
16.
FukumotoS., YamashitaT.FGF23 is a hormone-regulating phosphate metabolism–unique biological characteristics of FGF23.Bone2007; 40: 1190–5.
17.
RendinaD., MossettiG., De FilippoG., CioffiM., StrazzulloP.Fibroblast growth factor 23 is increased in calcium nephrolithiasis with hypophosphatemia and renal phosphate leak.J Clin Endocrinol Metab2006; 91: 959–63.
18.
KarimZ., GérardB., BakouhN.. NHERF1 mutations and responsiveness of renal parathyroid hormone.N Engl J Med2008; 359: 1128–35.
RendinaD., De FilippoG., StrazzulloP.NHERF1 mutations and responsiveness of renal parathyroid hormone.N Engl J Med2008; 359: 2616–7.
21.
EndoI., FukumotoS., OzonoK.. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.Bone2008; 42: 1235–9.
